Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors

BACKGROUND: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. METHODS: We reviewed the medical records o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Liancheng, Dong, Baijun, Chi, Chenfei, Wang, Yanqing, Gong, Yiming, Sha, Jianjun, Pan, Jiahua, Shangguan, Xun, Huang, Yiran, Zhou, Lixin, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276197/
https://www.ncbi.nlm.nih.gov/pubmed/30509237
http://dx.doi.org/10.1186/s12894-018-0416-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276197/
https://www.ncbi.nlm.nih.gov/pubmed/30509237
http://dx.doi.org/10.1186/s12894-018-0416-6

Ejemplares similares